Brexit and the EMA: what's next for the UK?

When Theresa May triggered Article 50 on 29 March, the UK began a two‐year process of negotiations to exit the EU, which is likely to include a divorce from the European Medicines Agency (EMA). But what will fill the gap left by the EMA and what will be the impact on new drugs coming to the market?

Source: Prescriber - May 31, 2017 Category: Primary Care Authors: Danny Buckland Tags: Report Source Type: research